Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

J Neurol. 2019 Oct 8. doi: 10.1007/s00415-019-09563-y. [Epub ahead of print]

PMID:
31595377
2.

A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis.

Kaufmann M, Puhan MA, Kuhle J, Yaldizli Ö, Magnusson T, Kamm CP, Calabrese P, von Wyl V.

Front Neurol. 2019 Sep 4;10:953. doi: 10.3389/fneur.2019.00953. eCollection 2019.

3.

How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.

Barin L, Kamm CP, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955. [Epub ahead of print]

PMID:
31456464
4.

Changes in the sex ratio are a good indicator of changes in MS incidence - Yes.

Ajdacic-Gross V, von Wyl V.

Mult Scler. 2019 Oct;25(12):1566-1568. doi: 10.1177/1352458519838780. Epub 2019 May 15. No abstract available.

PMID:
31088313
5.

Measuring diabetes guideline adherence with claims data: systematic construction of indicators and related challenges.

Ulyte A, Bähler C, Schwenkglenks M, von Wyl V, Gruebner O, Wei W, Blozik E, Brüngger B, Dressel H.

BMJ Open. 2019 Apr 24;9(4):e027138. doi: 10.1136/bmjopen-2018-027138.

6.

A step beyond the hygiene hypothesis-immune-mediated classes determined in a population-based study.

Ajdacic-Gross V, Mutsch M, Rodgers S, Tesic A, Müller M, Seifritz E, Wagner EN, von Känel R, Landolt MA, Steinemann N, von Wyl V, Castelao E, Strippoli MF, Glaus J, Vandeleur C, Marques-Vidal PM, Vollenweider P, Preisig M.

BMC Med. 2019 Apr 9;17(1):75. doi: 10.1186/s12916-019-1311-z.

7.
8.

Multiple Sklerose und Lebensqualität.

Vaney C, Barin L, Von Wyl V.

Rev Med Suisse. 2019 Jan 30;15(636):287-288. German. No abstract available.

PMID:
30724514
9.

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

Mult Scler J Exp Transl Clin. 2018 Dec 6;4(4):2055217318814562. doi: 10.1177/2055217318814562. eCollection 2018 Oct-Dec.

10.

Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study.

Barin L, Kaufmann M, Salmen A, Kamm CP, Gobbi C, Kuhle J, Pot C, Chan A, Czaplinski A, Ajdacic-Gross V, Rodgers S, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

Mult Scler Relat Disord. 2019 Feb;28:17-25. doi: 10.1016/j.msard.2018.11.033. Epub 2018 Dec 2.

PMID:
30530118
11.

Variation of preoperative chest radiography utilization in Switzerland and its influencing factors: a multilevel study with claims data.

Wei W, Gruebner O, von Wyl V, Brüngger B, Dressel H, Ulyte A, Blozik E, Bähler C, Schwenkglenks M.

Sci Rep. 2018 Nov 30;8(1):17475. doi: 10.1038/s41598-018-35856-9.

12.

The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research.

Steinemann N, Kuhle J, Calabrese P, Kesselring J, Disanto G, Merkler D, Pot C, Ajdacic-Gross V, Rodgers S, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

BMC Neurol. 2018 Aug 13;18(1):111. doi: 10.1186/s12883-018-1118-0.

13.

The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?

Barin L, Salmen A, Disanto G, Babačić H, Calabrese P, Chan A, Kamm CP, Kesselring J, Kuhle J, Gobbi C, Pot C, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

Mult Scler Relat Disord. 2018 Oct;25:112-121. doi: 10.1016/j.msard.2018.07.013. Epub 2018 Jul 21.

PMID:
30059895
14.

A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity.

Puhan MA, Steinemann N, Kamm CP, Müller S, Kuhle J, Kurmann R, Calabrese P, Kesselring J, von Wyl V, Swiss Multiple Sclerosis Registry Smsr.

Swiss Med Wkly. 2018 May 16;148:w14623. doi: 10.4414/smw.2018.14623. eCollection 2018.

15.

Recommended outcome measures for inpatient rehabilitation of multiple sclerosis are not appropriate for the patients with substantially impaired mobility.

Barin L, Vaney C, Puhan MA, von Wyl V.

Mult Scler Relat Disord. 2018 May;22:108-114. doi: 10.1016/j.msard.2018.04.001. Epub 2018 Apr 4.

PMID:
29655044
16.

Variability of Very Low Birth Weight Infant Outcome and Practice in Swiss and US Neonatal Units.

Adams M, Bassler D, Bucher HU, Roth-Kleiner M, Berger TM, Braun J, Puhan MA, Edwards E, Soll R, Von Wyl V; Swiss Neonatal Network and the Vermont Oxford Network.

Pediatrics. 2018 May;141(5). pii: e20173436. doi: 10.1542/peds.2017-3436. Epub 2018 Apr 13.

17.

Death at no cost? Persons with no health insurance claims in the last year of life in Switzerland.

Panczak R, von Wyl V, Reich O, Luta X, Maessen M, Stuck AE, Berlin C, Schmidlin K, Goodman DC, Egger M, Clough-Gorr K, Zwahlen M.

BMC Health Serv Res. 2018 Mar 14;18(1):178. doi: 10.1186/s12913-018-2984-2.

18.

Iron metabolism in patients with Graves' hyperthyroidism.

Fischli S, von Wyl V, Trummler M, Konrad D, Wueest S, Ruefer A, Heering K, Streuli R, Steuer C, Bernasconi L, Recher M, Henzen C.

Clin Endocrinol (Oxf). 2017 Nov;87(5):609-616. doi: 10.1111/cen.13450. Epub 2017 Sep 14.

19.

Comparison of three different methods for risk adjustment in neonatal medicine.

Adams M, Braun J, Bucher HU, Puhan MA, Bassler D, Von Wyl V; Swiss Neonatal Network.

BMC Pediatr. 2017 Apr 17;17(1):106. doi: 10.1186/s12887-017-0861-5.

20.

The change in the sex ratio in multiple sclerosis is driven by birth cohort effects.

Ajdacic-Gross V, Schmid M, Mutsch M, Steinemann N, von Wyl V, Bopp M.

Eur J Neurol. 2017 Jan;24(1):98-104. doi: 10.1111/ene.13160. Epub 2016 Sep 25.

PMID:
27666339
21.

Cancer co-occurrence patterns in Parkinson's disease and multiple sclerosis-Do they mirror immune system imbalances?

Ajdacic-Gross V, Rodgers S, Aleksandrowicz A, Mutsch M, Steinemann N, von Wyl V, von Känel R, Bopp M.

Cancer Epidemiol. 2016 Oct;44:167-173. doi: 10.1016/j.canep.2016.08.018. Epub 2016 Sep 6.

PMID:
27612279
22.

Regional Variation of Cost of Care in the Last 12 Months of Life in Switzerland: Small-area Analysis Using Insurance Claims Data.

Panczak R, Luta X, Maessen M, Stuck AE, Berlin C, Schmidlin K, Reich O, von Wyl V, Goodman DC, Egger M, Zwahlen M, Clough-Gorr KM.

Med Care. 2017 Feb;55(2):155-163. doi: 10.1097/MLR.0000000000000634.

23.

Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis.

Scherrer AU, von Wyl V, Yang WL, Kouyos RD, Böni J, Yerly S, Klimkait T, Aubert V, Cavassini M, Battegay M, Furrer H, Calmy A, Vernazza P, Bernasconi E, Günthard HF; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rudin C, Schöni-Affolter F, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Weber R, Yerly S.

Clin Infect Dis. 2016 May 15;62(10):1310-1317. doi: 10.1093/cid/ciw128. Epub 2016 Mar 8.

PMID:
26962075
24.

Failure to pay for social health insurance premiums: Acts of protest or desperation?

von Wyl V, Beck K.

Prev Med Rep. 2015 Feb 7;2:127-33. doi: 10.1016/j.pmedr.2015.02.001. eCollection 2015.

25.

Cost trajectories from the final life year reveal intensity of end-of-life care and can help to guide palliative care interventions.

von Wyl V, Telser H, Weber A, Fischer B, Beck K.

BMJ Support Palliat Care. 2018 Sep;8(3):325-334. doi: 10.1136/bmjspcare-2014-000784. Epub 2015 Oct 15.

PMID:
26470876
26.

Risk adjustment in aging societies.

von Wyl V, Beck K.

Health Econ Rev. 2014 Dec;4(1):7. doi: 10.1186/s13561-014-0007-5. Epub 2014 Aug 9.

27.

Do insurers respond to risk adjustment? A long-term, nationwide analysis from Switzerland.

von Wyl V, Beck K.

Eur J Health Econ. 2016 Mar;17(2):171-83. doi: 10.1007/s10198-015-0669-x. Epub 2015 Feb 8.

PMID:
25663430
28.

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.

Metzner KJ, Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Hirsch HH, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

AIDS. 2014 Sep 24;28(15):2231-9. doi: 10.1097/QAD.0000000000000397.

29.

Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.

von Wyl V, Klimkait T, Yerly S, Nicca D, Furrer H, Cavassini M, Calmy A, Bernasconi E, Böni J, Aubert V, Günthard HF, Bucher HC, Glass TR; Swiss HIV Cohort Study.

PLoS One. 2013 Oct 16;8(10):e77691. doi: 10.1371/journal.pone.0077691. eCollection 2013.

30.

Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study.

Drescher SM, von Wyl V, Yang WL, Böni J, Yerly S, Shah C, Aubert V, Klimkait T, Taffé P, Furrer H, Battegay M, Ambrosioni J, Cavassini M, Bernasconi E, Vernazza PL, Ledergerber B, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

Clin Infect Dis. 2014 Jan;58(2):285-94. doi: 10.1093/cid/cit694. Epub 2013 Oct 21.

31.

The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.

Beerenwinkel N, Montazeri H, Schuhmacher H, Knupfer P, von Wyl V, Furrer H, Battegay M, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Yerly S, Böni J, Klimkait T, Cellerai C, Günthard HF; Swiss HIV Cohort Study.

PLoS Comput Biol. 2013;9(8):e1003203. doi: 10.1371/journal.pcbi.1003203. Epub 2013 Aug 29.

32.

Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.

Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Battegay M, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2013 Oct 1;208(7):1102-12. doi: 10.1093/infdis/jit310. Epub 2013 Jul 11.

33.

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN.

PLoS One. 2012;7(8):e42834. doi: 10.1371/journal.pone.0042834. Epub 2012 Aug 8.

34.

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.

Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Cellerai C, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Günthard HF; Swiss HIV Cohort Study.

PLoS One. 2012;7(6):e37983. doi: 10.1371/journal.pone.0037983. Epub 2012 Jun 18.

35.

Assessing predicted HIV-1 replicative capacity in a clinical setting.

Kouyos RD, von Wyl V, Hinkley T, Petropoulos CJ, Haddad M, Whitcomb JM, Böni J, Yerly S, Cellerai C, Klimkait T, Günthard HF, Bonhoeffer S; Swiss HIV Cohort Study.

PLoS Pathog. 2011 Nov;7(11):e1002321. doi: 10.1371/journal.ppat.1002321. Epub 2011 Nov 3.

36.

Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.

von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2012 Jan 1;54(1):131-40. doi: 10.1093/cid/cir728. Epub 2011 Nov 4.

37.

Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M.

Scherrer AU, von Wyl V, Götte M, Klimkait T, Cellerai C, Yerly S, Böni J, Held L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):105-12. doi: 10.1097/QAI.0b013e31823c8b69.

PMID:
22027876
38.

Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.

Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2011 Dec;53(11):1143-52. doi: 10.1093/cid/cir669. Epub 2011 Oct 13.

39.

High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease.

Schüpbach J, Bisset LR, Regenass S, Bürgisser P, Gorgievski M, Steffen I, Andreutti C, Martinetti G, Shah C, Yerly S, Klimkait T, Gebhardt M, Schöni-Affolter F, Rickenbach M; Swiss HIV Cohort Study, Barth J, Battegay M, Bernascon E, Böni J, Bucher HC, Bürgisser P, Burton-Jeangros C, Calmy A, Cavassini M, Dubs R, Egger M, Elzi L, Fehr J, Fischer M, Flepp M, Francioli P, Furrer H, Fux CA, Gorgievski M, Günthard H, Hasse B, Hirsch HH, Hirschel B, Hösli I, Kahlert C, Kaiser L, Keiser O, Kind C, Klimkait T, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Müller N, Nadal D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schmid P, Schultze D, Schöni-Affolter F, Schüpbach J, Speck R, Taffé P, Telenti A, Trkola A, Vernazza P, von Wyl V, Weber R, Yerly S.

BMC Infect Dis. 2011 Sep 26;11:254. doi: 10.1186/1471-2334-11-254.

40.

Estimating the basic reproductive number from viral sequence data.

Stadler T, Kouyos R, von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Joos B, Rieder P, Xie D, Günthard HF, Drummond AJ, Bonhoeffer S; Swiss HIV Cohort Study.

Mol Biol Evol. 2012 Jan;29(1):347-57. doi: 10.1093/molbev/msr217. Epub 2011 Sep 2.

PMID:
21890480
41.

The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland.

von Wyl V, Kouyos RD, Yerly S, Böni J, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Staehelin C, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2011 Oct 1;204(7):1095-103. doi: 10.1093/infdis/jir491.

42.

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.

Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD; EuroSIDA in EuroCoord.

HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x. Epub 2011 Aug 17.

43.

Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study.

Røysland K, Gran JM, Ledergerber B, von Wyl V, Young J, Aalen OO.

Stat Med. 2011 Oct 30;30(24):2947-58. doi: 10.1002/sim.4324. Epub 2011 Jul 29.

PMID:
21800346
44.

Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.

Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2011;16(4):535-45. doi: 10.3851/IMP1776.

PMID:
21685541
45.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

46.

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.

Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G; EuroCoord-CHAIN study group.

Lancet Infect Dis. 2011 May;11(5):363-71. doi: 10.1016/S1473-3099(11)70032-9. Epub 2011 Feb 25.

PMID:
21354861
47.

Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.

Scherrer AU, von Wyl V, Joos B, Klimkait T, Bürgisser P, Yerly S, Böni J, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2011 Mar 15;203(6):791-7. doi: 10.1093/infdis/jiq130. Epub 2011 Feb 1.

48.

Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.

Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Garzoni C, Hirschel B, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (SHCS).

J Acquir Immune Defic Syndr. 2011 May 1;57(1):24-31. doi: 10.1097/QAI.0b013e318211925e.

PMID:
21283013
49.

Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.

Fehr J, Glass TR, Louvel S, Hamy F, Hirsch HH, von Wyl V, Böni J, Yerly S, Bürgisser P, Cavassini M, Fux CA, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard HF, Battegay M, Bucher HC, Klimkait T; Swiss HIV Cohort Study.

J Transl Med. 2011 Jan 21;9:14. doi: 10.1186/1479-5876-9-14.

50.

Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.

Kouyos RD, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Rauch A, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2011 Feb 15;52(4):532-9. doi: 10.1093/cid/ciq164. Epub 2011 Jan 10.

Supplemental Content

Loading ...
Support Center